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Unconventional T cells are defined by their capacity to respond to signals other than the 
well-known complex of peptides and major histocompatibility complex proteins. Among 
the burgeoning family of unconventional T cells, innate-like CD8(+) T cells in the mouse 
were discovered in the early 2000s. This subset of CD8(+) T  cells bears a memory 
phenotype without having encountered a foreign antigen and can respond to innate-like 
IL-12 + IL-18 stimulation. Although the concept of innate memory CD8(+) T cells is now 
well established in mice, whether an equivalent memory NK-like T-cell population exists 
in humans remains under debate. We recently reported that CD8(+) T cells respond-
ing to innate-like IL-12 +  IL-18 stimulation and co-expressing the transcription factor 
Eomesodermin (Eomes) and KIR/NKG2A membrane receptors with a memory/EMRA 
phenotype may represent a new, functionally distinct innate T cell subset in humans. In 
this review, after a summary on the known innate CD8(+) T-cell features in the mouse, we 
propose Eomes together with KIR/NKG2A and CD49d as a signature to standardize the 
identification of this innate CD8(+) T-cell subset in humans. Next, we discuss IL-4 and 
IL-15 involvement in the generation of innate CD8(+) T cells and particularly its possible 
dependency on the promyelocytic leukemia zinc-finger factor expressing iNKT cells, an 
innate T cell subset well documented for its susceptibility to tumor immune subversion. 
After that, focusing on cancer diseases, we provide new insights into the potential role of 
these innate CD8(+) T cells in a physiopathological context in humans. Based on empir-
ical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome 
controlled by the immune system, and in solid tumors, we observe both the possible 
contribution of innate CD8(+) T cells to cancer disease control and their susceptibility to 
tumor immune subversion. Finally, we note that during tumor progression, innate CD8(+) 
T lymphocytes could be controlled by immune checkpoints. This study significantly con-
tributes to understanding of the role of NK-like CD8(+) T cells and raises the question of 
the possible involvement of an iNKT/innate CD8(+) T cell axis in cancer.
Keywords: innate memory Cd8(+) t cells, nK-like t cells, inKt cells, natural killer receptors, eomesodermin, 
Cd49d, chronic myeloid leukemia, solid cancers
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introdUCtion
The traditional view of the immune system distinguishes innate 
immunity from adaptive or acquired immunity. Innate immunity 
is derived from cells expressing the receptors specific for molecules 
from microbial pathogens called pathogen-associated molecu-
lar patterns or self-molecules from the healthy or unhealthy 
individual called damage-associated molecular patterns. One of 
the key characteristics of innate immunity effector mechanisms 
is their capacity for very rapid response to pro-inflammatory 
cytokines such as IL-12, IL-18, and IL-33.
The effectors of adaptive immunity possess receptors charac-
terized by highly diverse and specific antigens. A major feature of 
adaptive immunity consists in its serving as an essential support 
for the immunologic memory, which means that it can remember 
and quite effectively respond to an antigen long after having 
encountered it for the first time.
However, numerous works over the past 20  years have 
shown the distinction between innate immunity and adaptive 
immunity to be less clear-cut and more tenuous than it first 
appeared. This revised perception is based, in particular, on 
description of non-conventional T cells responding to stimuli 
that had previously been considered as being recognized solely 
by innate cells. These populations of T lymphocytes include not 
only certain T-cell receptor (TCR)-γδ cells but also TCR-αβ 
cells such as natural killer T (iNKT) cells and innate mucosal-
associated invariant T (MAIT) cells [for a list of the different 
cells, see Ref. (1, 2)].
A new contingent of innate T cells was described in the early 
2000s in the mouse, partially in the thymus, where they were 
termed «innate memory» (IM) CD8(+) T  cells, and partially 
in the spleen, where they were termed «virtual memory» (VM) 
CD8(+) T cells (3, 4). Aside from possessing a phenotype of acti-
vated memory cells, one characteristic of these cells consists in 
their differentiating into memory cells independently of a foreign 
antigen. In parallel, CD8(+) T cells in humans were described 
as cells possessing innate characteristics including NK markers. 
They were found in human cord blood, a finding consistent 
with the hypothesis that their development does not depend on 
foreign antigens. These cells hence were termed NK-like CD8(+) 
T cells.
At the outset of this review, we shall compare the human 
NK-like CD8(+) T cells with IM/VM CD8(+) T cells in mice. 
On the basis of this comparison and with regard to humans, 
we shall focus first on expression of the transcription factor 
Eomesodermin (Eomes) as a lineage marker of that population 
of cells, and then on their innate functions (cytotoxicity and 
TCR-independent IFN-γ expression), along with their memory 
phenotype, and on the roles of IL-4- and promyelocytic leukemia 
zinc-finger factor (PLZF)-expressing T cells in differentiation of 
these cells, hereafter referred to as innate CD8(+) T  cells. We 
shall discuss the use of membrane markers, particularly the 
α4-integrin CD49d, in order to obtain a more well-defined 
phenotype correlating with their functions and/or explaining 
their possible physiological role. Finally, we shall discuss the 
implication of innate CD8(+) T cells in anticancer immunity in 
humans.
innate Cd8(+) t LyMpHoCytes in MiCe
Studies conducted shortly after 2000 by Forman et  al. (5, 6) 
demonstrated the existence of CD8(+) T cells producing IFN-γ 
in response to innate signals occurring independently from the 
TCR. These CD8(+) T cells possessed a CD44(+) CD62L(−) 
CD122(+) memory phenotype and, in  vivo, provided pro-
tection against Listeria monocytogenes (LM) infection (5–7). 
Their mobilization depended on the production of IL-12 and 
IL-18. Interestingly, the Forman team subsequently showed 
that this cell population was present in the thymus of C57BL/6 
wild-type mice and that it was enriched in C57BL/6 H-2 
Kb−/−Db−/− mice not having undergone stimulation by foreign 
antigens (7).
A second series of studies having to do with Itk−/− (induc-
ing T  cell kinase), Rlk−/− (resting lymphocyte kinase), or 
Itk−/−Rlk−/− mice led to identification of a population of thymic 
CD8(+) T  cells expressing an activated memory [CD44(+) 
CD62L(−) CD122(+)] phenotype and called IM CD8(+) 
T  cells (8–12). Interestingly, these cells developed in the 
thymus and are exported to the spleen and the lymph nodes 
(LNs) where they could fulfill an anti-infective function against 
LM, particularly through production of IFN-γ following TCR-
independent stimulation by IL-12 and IL-18. An important 
point in the studies dedicated to this population has been the 
demonstration that its differentiation depended on expression 
of the Eomes transcription factor and IL-15 (13–15). Eomes 
expression initiates the differentiation program of these cells 
and induces the expression of CD122 (the β chain of the IL-2 
and IL-15 receptor). IL-15 has a critical role in the expansion 
of IM CD8(+) T  cells (8, 16). It should also be noted that 
this population is present in Itk−/−Kb−/−Db−/− mice, a finding 
suggesting that at least some IM CD8(+) T  cells are selected 
by non-classical major histocompatibility complex (MHC) class 
I molecules (9, 17–19).
A final series of studies has described in mouse spleens 
and peripheral lymphoid organs a population of activated 
[CD122(+)] and memory [CD44(+) CD62L(−)] CD8(+) 
T  lymphocytes of which the differentiation into memory cells 
occurs independently of any recognition of a foreign antigen. 
This population consists in the so-called VM CD8(+) T  cells. 
As is the case with IM T CD8(+) cells, Eomes and IL-15 are 
the two key factors in their differentiation. This population is 
capable of producing IFN-γ in response to innate stimulation by 
IL-12 + IL-18 (11, 20–22).
The expression by mouse thymic IM CD8(+) T cells of some 
integrins, such as CD49d [an α4-integrin, or VLA-α4, which 
is most often matched with a β7-integrin (which is bound to 
Madcam and VCAM-1 or CD106), or a β1-integrin], has been 
described (14, 21, 23, 24). Hence, CD49d is used to discriminate 
between IM and VM T  cells (Figure  1A) arising from the 
thymus or the spleen, respectively. In this model, a possible 
filiation link between IM CD8(+) and VM CD8(+) T-cell 
populations remains to be investigated. A gating strategy to 
identify IM/VM CD8(+) T cells in mice, taking Eomes, CD44, 
and CD122 together with CD49d as delineating markers is 
depicted in Figure 1B and Figure S1 in Supplementary Material. 
FigUre 1 | the innate/true memory (iM/tM) and virtual memory (VM) Cd8(+) t cells in mice. (a) Representative view of IM/TM and VM CD8(+) T cells in 
mice. CXCR3(+) CD122(+) CD44(+) CD49d(+) Eomes(+) and CXCR3(+) CD122(+) CD44(+) Eomes(+) T-bet(+) expression defined the IM/TM CD8(+) and the VM 
CD8(+) T-cell subsets, respectively. Both subsets have the capacity to respond to the IL-12 + IL-18 innate-like stimulation, and their development and homeostasis 
are regulated by IL-4 [mainly produced by PLZF(+) iNKT cells], IL-15, and type I interferons. Note that possible existence of a filiation link in mice between IM CD8(+) 
and VM CD8(+) T-cell populations remains to be investigated. (B) Gating strategy in C57BL/6 and BALB/c mouse strains for IM and VM CD8(+) T cells in the 
thymus (left panel) and for TM and VM CD8(+) T cells in the spleen (right panel). IM/TM and VM population frequencies are displayed in the upper and lower right 
quadrants, respectively.
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Based on this gating strategy, in the C57BL/6 mouse strain, 
the vast majority of memory [CD44(+) Eomes(+) CD122(+)] 
CD8(+) T cells are IM CD8(+) T cells in the thymus vs. VM 
CD8(+) T  cells in the spleen, as attested by their differential 
CD49d expression. Interestingly, in the BALB/c strain, thymic 
IM CD8(+) T cells are minority cells among memory CD44(+) 
CD122(+) Eomes(+) cells, raising the question of a possible link 
between IM and VM CD8(+) T cells, as well as the association 
of CD49d with the innate functions of IM/VM CD8(+) T cells 
(see CD49d, a Functional Marker of Innate CD8(+) T Cells 
in Humans).
IL-15 plays a key role in the homeostatic expansion of CD8(+) 
T  cells, and it has been reported in several studies that this 
cytokine is implicated in differentiation into VM CD8(+) T cells 
after homeostatic proliferation (4, 25–28). However, August and 
his team have shown that the size of the IM/VM CD8(+) T popu-
lation is not modified by T-cell depletion prior to bone marrow 
transplantation, a finding suggesting that lymphoid precursors 
are differentiated into IM/VM CD8(+) T cells following “tuning” 
by cells expressing MHC class I molecules. Moreover, in the same 
study, IM/VM CD8(+) T cells are distinguished from homeostatic 
proliferation CD8(+) T cells by a different transcriptional profile 
(29). Another study suggests that contrary to naive CD8(+) 
T cells and homeostatic proliferation CD8(+) T cells, acquisition 
of the phenotype of IM CD8(+) T cells necessitates engagement 
of their TCR (30).
eVidenCe For nK-LiKe Cd8(+) t CeLLs 
in HUMans
In parallel with the previously described work on mice, sev-
eral studies conducted in the early 2000s demonstrated the 
existence in humans of CD8(+) T  cell-expressing markers 
and receptors of NK cells including CD56, KIR, NKG2A and 
NKG2C (CD159a and c), and CD94 (31–36). Several studies 
precisely characterized the phenotype of the KIR(+) CD8(+) 
T  cells and showed that they possess an EMRA memory 
phenotype [CD45RA(+) CCR7(−) CD57(+)] (33, 34). Finally, 
Björkström et al. (33), showed that EMRA(+) KIR(+) CD8(+) 
T cells have a skewed repertoire using fewer different Vβ than 
their EMRA(+) KIR(−) CD8(+) T cell counterpart, a finding 
suggesting the role of antigenic pressure in the acquisition 
of this phenotype. An equivalent to this population of KIR/
NKG2(+) CD8(+) T  cells is present in human cord blood, 
where they possess an EMRA memory phenotype and rapidly 
express IFN-γ following TCR stimulation (36). In fact, this 
is a population of T  cells that has been educated and has 
differentiated in the absence of foreign antigenic stimulation, 
into terminal effector memory T cells.
These KIR(+) CD8(+) T cells have a weaker response to TCR 
stimulation than their KIR(−) CD8(+) counterparts with regard 
to the expression of IFN-γ and TNF-α or to the degranulation 
evaluated by CD107a staining. The KIR(+) CD8(+) T  cells 
expressing two different KIRs have a weaker response to TCR 
stimulation than cells expressing a single KIR or without KIR (33, 
34). Remarkably, this CD56(+) [or KIR(+)] CD8(+) T cell subset 
responds quite effectively to innate stimuli, one example being 
the association of IL-12 with IL-18 (37). The same team reported 
that loss of this function in IL-12R−/− patients is associated with 
a risk of severe infections from intracellular germs, particularly 
mycobacteria and Salmonella (37).
HUMan nK-LiKe Cd8(+) t CeLLs 
eXpress eoMes and dispLay innate 
FUnCtions
The study by Jacomet et  al. (38) showed that KIR(+) and/or 
NKG2A(+) CD8(+) T cells preferentially express Eomes. These 
KIR/NKG2A(+) Eomes(+) CD8(+) T  cells have a memory 
phenotype and share functional and phenotypic features (4, 
38) with IM CD8(+) T  cells in mice (8–11). Moreover, with 
respect to KIR/NKG2A(−) CD8(+) T  cells, they possess an 
EMRA phenotype [CD45RA(+) CCR7(−)] and preferentially 
express the surface molecule CD57, which is a terminal 
differentiation marker (Figure  2A). Figure  2B shows a gat-
ing strategy designed to analyze these cells in human blood. 
Remarkably, the majority (around 60–70%) of KIR/NKG2A(+) 
Eomes(+) CD8(+) T cells express the T-box transcription fac-
tor T-bet, a phenotype comparable to the phenotype described 
for mouse VM CD8(+) T cells (22). These cells are character-
ized by increased frequency of CD16(+) cells in comparison 
to conventional memory [KIR/NKG2A(−) Eomes(+)] CD8(+) 
T  cells. Moreover, CD16 expression is substantially increased 
in KIR/NKG2A(+) Eomes(+) CD8(+) T cells following 48 h of 
IL-15 in vitro treatment (Figure 3A).
Together with their marked NK-like phenotype, a hallmark 
of KIR/NKG2A(+) Eomes(+) CD8(+) T cells is their capacity 
to rapidly produce large amounts of IFN-γ in response to 
innate-like stimulation by IL-12  +  IL-18 (38). So it is that 
among the CD8(+) T cells, 60–70% of those possessing a capac-
ity for innate response to IL-12 +  IL-18 are KIR/NKG2A(+) 
Eomes(+) CD8(+) T cells. Moreover, the frequency of the cells 
producing IFN-γ in response to IL-12  +  IL-18 stimulation 
is four times greater than that of the same cells stimulated 
with anti-CD3 and anti-CD28 agonistic monoclonal antibodies 
(mAbs) (38). In the same way, these cells possess a cytotoxic 
arsenal: perforin and granzyme B. They possess an innate 
cytotoxic potential induced by an anti-CD16 antibody and 
revealed by the CD107a test, which assesses degranulation 
(38). In the final analysis, these data demonstrate that KIR/
NKG2A(+) Eomes(+) CD8(+) T  cells display innate activity 
by responding to innate stimuli with response efficacy greater 
than that of their response to adaptive stimuli (i.e., via their 
TCR), as has also been shown for innate T-cell populations 
such as dendritic epidermal T  cells (39).
A final element appearing to favor the innate character of 
KIR/NKG2A(+) Eomes(+) CD8(+) T  cells is their differen-
tiation without any exogenous antigenic stimulation, as it is 
possible to show the existence of these cells in the fetal thymus 
(40), and as our team has shown them to be present in cord 
blood. Interestingly, in cord blood, they express an EMRA 
phenotype with a lower CD57 cell frequency than in the adult, 
suggesting that there exist supplementary steps in the terminal 
maturation of these peripheral cells (38). Functionally, as is the 
FigUre 2 | the innate Cd8(+) t cells in humans. (a) Representative view of human innate CD8(+) T cells. The membrane markers KIR/NKG2A, CD56, CD57, 
CD45RA, and CD49d and nuclear transcription factors Eomes and T-bet define this new unique innate CD8(+) T-cell population [for details, see Ref. (4, 38)]. Innate 
CD8(+) T cells in humans have the capacity to respond to IL-12 + IL-18 innate-like stimulation. Their development and homeostasis are regulated by IL-15, IL-4 
[presumably by PLZF(+) iNKT cells], and expectedly type I interferons. Note that the precise origin (central vs. peripheral) of innate CD8(+) T-cell populations in 
humans remains under debate. (B) Gating strategy for innate CD8(+) T cells among peripheral blood mononuclear cells from healthy donors. After gating on T-cell 
receptor (TCR)-αβ(+) CD8(+) cells, the innate CD8(+) T cells are defined as KIR/NKG2A(+) Eomes(+). Frequency of innate CD8(+) T cells is displayed in the upper 
right corner.
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case in adult cells, these KIR/NKG2A(+) Eomes(+) CD8(+) 
T  cord blood cells express IFN-γ after innate-like stimulation 
by IL-12 +  IL-18.
All in all, we described for the first time a CD8(+) T  cells 
population with innate features by associating Eomes and KIR/
NKG2A markers with the capacity to respond to IL-12 + IL-18 
stimulation. These features validate the KIR/NKG2A(+) 
Eomes(+) CD8(+) T-cell compartment as a new member of the 
innate T cell family in humans, and we have termed them innate 
CD8(+) T cells (41).
There exist a number of hypotheses on the mechanisms 
involved in the reprogramming of conventional T lymphocytes 
into innate CD8(+) T lymphocytes. One of these assumptions is 
based on a cross talk between IL-12R and TCR signalosome, in 
which IL-12 recruits Tyk2 and Fyn tyrosine kinases to activate 
CD3ζ–TCR signal transduction pathways (42).
Some studies conducted in mice suggest that IM and/or VM 
CD8(+) T  cells could be selected by non-classical MHC class 
I molecules (9, 17–19). In humans, our results (Figure S2 in 
Supplementary Material) show that a relatively small fraction 
of KIR/NKG2A(+) Eomes(+) CD8(+) cells are MAIT  cells. 
This finding suggests that at least some human innate CD8(+) 
T cells could be selected by non-classical class I MHC molecules, 
and it raises the possibility of the presence in this population 
of cells being restricted by non-classical MHC class I HLA-E 
molecules (18).
Cd49d, a FUnCtionaL MarKer oF 
innate Cd8(+) t CeLLs in HUMans
We have sought out other markers of innate CD8(+) T  cells 
in humans. Among them, we tested CD56, a marker in 
humans associated with NK cells, but our results showed that 
this marker is no more effective in distinguishing the innate 
CD8(+) T-cell population than the KIR/NKG2A markers. 
More precisely, this marker delineate only 20–30% of the 
CD8(+) T  cells expressing IFN-γ after innate stimulation by 
IL-12 + IL-18 (as opposed to the approximately 70% exhibited 
by the KIR/NKG2A markers) [data not shown; (38)]. We also 
tested CD161, of which the expression is a common feature 
of human innate T cell subsets including iNKT cells, TCR-γδ 
T  cells, and MAIT  cells (43). However, as for CD56, CD161 
is expressed by only approximately 20% of the Eomes(+) KIR/
NKG2A(+) CD8(+) T  cells (Figure  3B).
Reasoning by analogy with the mouse model, we tested 
CD49d expression by innate CD8(+) T  cells in humans 
(Figures 4A,B). Interestingly, the CD8(+) T cells with the KIR/
NKG2A(+) Eomes(+) phenotype strongly expressed CD49d, as 
compared to the CD8(+) T-cell population taken as a whole 
(Figure 4A). Moreover, the majority (almost 70%) of the cells 
with a more pronounced expression of CD49d consisted in those 
expressing IFN-γ after innate-like stimulation by IL-12 + IL-18 
(Figure 4B). These results show CD49d to be closely associated 
FigUre 3 | Cd16 and Cd161 are slightly enriched in innate Cd8(+) 
t cells. (a) Peripheral blood mononuclear cells (PBMCs) from healthy 
donors (HDs) (n = 6) were cultured for 48 h in the presence of IL-15 and 
then analyzed by flow cytometry. One representative sample is shown for 
CD16 expression among total (upper panel) and innate (lower panel) CD8(+) 
T-cell subsets. Frequencies are displayed in the gate and the histogram (right 
panel) presents the full cohort of CD16-positive cells (mean ± SD) in both 
T-cell subsets. (B) PBMCs from HD (n = 9) were analyzed ex vivo by flow 
cytometry. One representative sample is shown for CD161 expression 
among total (upper panel) and innate (lower panel) CD8(+) T-cell subsets. 
Frequencies are displayed in the gates (left panel). The histogram (right 
panel) represents the full cohort of CD161-positive cells (mean ± SD) in both 
T-cell subsets.
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with the innate effector functions of the innate CD8(+) T cells. 
On the other hand, CD49d cannot substitute for Eomes and 
KIR/NKG2A, given the fact that only 20–40% of CD49d(+) cells 
are actually innate CD8(+) T cells (Figure S3 in Supplementary 
Material). However, as innate CD8(+) T  cells arise from the 
thymus, the functional link between higher CD49d expression 
and IFN-γ secretion in response to IL-12 +  IL-18 stimulation 
should be tested in cord blood, which is an accessible source 
of cells providing an approximate reflection of thymic cells in 
humans.
These results have led us to inquire about the biological mean-
ing of CD49d expression by thymic vs. splenic (or IM vs. VM) 
CD8(+) T lymphocytes in mice. The results of several teams (14, 
21) suggest that contrary to thymic IM CD8(+) cells, splenic 
(so-called VM) innate CD8(+) T  cells do not express CD49d 
(14, 21) (Figure  1). We have observed, as in humans, that a 
large majority of splenic CD8(+) T cells expressing IFN-γ after 
innate-like stimulation by IL-12 +  IL-18 were those harboring 
the IM [Eomes(+) CD44(+) CD122(+)] phenotype (Figure 4C). 
Moreover, these IFN-γ-producing cells were mostly those that 
more pronouncedly expressed CD49d as compared to the total 
CD8(+) T-cell population (Figure 4D).
Taken as a whole, these different results suggest that CD49d 
is associated with the innate-like functions of NK-like CD8(+) 
T cells as much in humans as in mice. According to the β chain 
with which CD49d is matched, the cells are variably liable to 
migrate toward different territories. While the α4β7-integrin 
is associated with the migration of T  lymphocytes toward the 
digestive mucosa, the α4β1-integrin is associated with migration 
toward the oral mucosa, the salivary glands, the vaginal mucosa, 
and the central nervous system (44, 45). Indeed, therapeutic 
targeting of CD49d is used in treatment of multiple sclerosis 
(MS). Several studies have documented the implication of 
CD49d in the penetration of pathogenic T  lymphocytes dur-
ing MS or experimental allergic encephalomyelitis (EAE) (46, 
47). Taken together, these different observations raise the 
possibility of the implication of the innate CD8(+) T  cells in 
the pathogenesis of MS/EAE.
tHe FaCtors assoCiated/iMpLiCated 
in ControL oF tHe diFFerentiation 
oF innate Cd8(+) t LyMpHoCytes
In mice, differentiation of IM CD8(+) T  lymphocytes depends 
on soluble factors such as type I IFN and the IL-4 and IL-15 
cytokines.
Several studies have shown that IL-4 favors the arising of 
VM CD8(+) T  cells (48–51). More recent studies confirm 
the involvement of IL-4 in IM/VM CD8(+) T  cell generation 
with a more critical role being assumed in the BALB/c (22, 
30) than in the C57BL/6 mouse strain (14). IL-4-producing 
PLZF(+) T cells, including at least partially iNKT lymphocytes 
(52, 53), elicit the generation of IM CD8(+) T  cells. Other 
results from the Hogquist group confirm the link between 
iNKT PLZF(+) cells, IL-4, and IM CD8(+) T  cell generation 
by comparing different mouse strains (22). Figure  1B shows 
the higher frequency of T CD8(+) IM in the thymus of BALB/c 
in comparison with C57BL/6 mice. However, the August group 
shows results suggesting that IL-4 produced by differentiat-
ing CD4(+) CD8(+) double-positive thymocytes controls the 
generation of IM CD8(+) thymocytes in the Itk−/− C57BL/6 
background (16, 29). As concerns VM CD8(+) T lymphocytes, 
IL-4 is likewise at least partially implicated. IL-4 is likely to 
act by eliciting Eomes expression, of which the action would 
entail a heightened level of expression of CD122, and thereby 
sensitize the cells to IL-15 (14, 16).
Type I IFNs such as IFN-β and/or IFN-α (24) could favor the 
differentiation of lymphocytes to VM and/or IM CD8(+) T lym-
phocytes. The underlying mechanism described by the authors 
is the induction of Eomes expression by naive CD8(+) T cells.
Finally, IL-15 is a determining factor in the maintenance 
and/or homeostatic expansion of IM and VM CD8(+) T  cells 
(8, 14, 16).
FigUre 4 | the Cd49d molecule correlates with the innate function of innate Cd8(+) t cells in mice and humans. (a) Peripheral blood mononuclear cells 
(PBMCs) from healthy donors (HDs) (n = 6) were analyzed ex vivo by flow cytometry for CD49d expression in total and innate CD8(+) T cells. One representative 
sample is shown (left): total CD8(+) T cells (solid dark line), innate CD8(+) T cells (dotted black line), and isotype control (gray). Full cohort (MFI ± SD) is shown on the 
histogram (right). (B) PBMCs from HD (n = 5) were cultured 48 h in the presence of IL-12 + IL-18 and then analyzed ex vivo by flow cytometry for CD49d 
expression. Distribution of CD49d (percentage ± SD) in total CD8(+) T cells and in IFN-γ(+) CD8(+) T cells is shown on the histogram (right). One representative 
sample is shown (left): total CD8(+) T cells (solid dark line), IFN-γ(+) CD8(+) T cells (dotted black line), and isotype control (gray). (C,d) Splenocytes from Eomes-
GFP mice were isolated, cultured for 16 h in the presence of IL-12 + IL-18, and analyzed by flow cytometry. (C) One representative sample is shown for the 
presence of CD44(+) Eomes(+) and CD44(+) CD122(+) cells among total CD8(+) (upper left panel) or IFN-γ(+) CD8(+) T cells (lower left panel). Frequency of each 
subset is displayed in the gate. Full cohort frequencies for CD44(+) Eomes(+) (upper histogram) and CD44(+) CD122(+) (lower histogram) cells among total CD8(+) 
and IFN-γ(+) CD8(+) T cells are shown. (d) CD49d expression was analyzed in total and IFN-γ(+) CD8(+) T cells. One representative sample is shown (upper panel): 
total CD8(+) T cells (solid dark line), IFN-γ(+) CD8(+) T cells (dotted black line), and isotype control (gray). Full cohort histograms for frequencies of CD49d(low) and 
CD49d(bright) are shown (lower panel) in total CD8(+) and IFN-γ(+) CD8(+) T cells.
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Few studies have addressed the role of these factors 
in the development of innate CD8(+) T  cells in humans 
(38,  40). Interestingly, our own results (38) have shown a 
relation of proportionality between PLZF expression in T and 
iNKT  lymphocytes and Eomes expression by innate CD8(+) 
T  cells in cord blood, suggesting that iNKT  cells control the 
differentiation of human innate CD8(+) T  cells. Our results 
in  vitro (41) suggest that IL-4 favors Eomes expression and 
the generation and/or expansion of human innate CD8(+) 
T cells.
BoX 2 | Functional deficiency of inKt cells in chronic phase of CML 
(CML-Cp) patients.
Our team has shown in CML-CP patients at diagnosis a major defect in 
the iNKT  lymphocyte functions, particularly as concerns their proliferative 
response to T-cell receptor (TCR) stimulation (63) and their cytotoxic arsenal, 
with a loss in the expression of perforin and FasL, two elements implicated 
in cancer immunosurveillance by iNKT cells in mice (57, 64). It must also be 
emphasized that the iNKT cells of CML-CP patients have lost their expression 
of the transcription factor promyelocytic leukemia zinc-finger factor and 
no longer produce IL-4 during TCR engagement; on the other hand, they 
show normal expression of IFN-γ in comparison with the iNKT lymphocytes 
of healthy donors or patients in complete remission following treatment by 
tyrosine kinase inhibitors such as imatinib mesylate (63).
BoX 1 | Chronic myeloid leukemia (CML), a myeloproliferative 
syndrome controlled by the immune system.
Chronic myeloid leukemia is the first malignant disorder with a specific genetic 
abnormality in the background. It is due to the formation of the chimeric 
oncogene BCR–ABL. This oncogene is responsible for the transformation of 
hematopoietic stem cells (HSC) into leukemic stem cells, which results in a 
leukemic syndrome of mature myeloid cells characterizing the chronic phase 
(CP) and ineluctably evolving, without treatment, to acute leukemia (59). 
The ABL domain of the chimeric oncogene BCR–ABL presents deregulated 
tyrosine kinase activity, which is responsible for the transformation of the 
HSC. Since the outset of the 2000s, new CML treatment has consisted in 
the tyrosine kinase inhibitors of BCR–ABL. Some arguments suggest that 
CML is a disease in which the immune system has a key role [for review, see 
Ref. (60)]. In addition, during the chronic phase of CML, numerous innate 
anomalies in the innate immune system have been evidenced. Indeed, 
defective differentiation of the plasmacytoid dendritic cells, defective IFN-α 
production by mononuclear cells, and defective functions of NK cells have 
been observed (61, 62).
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is tHere a roLe For innate Cd8(+)  
t LyMpHoCytes in CanCer 
iMMUnosUrVeiLLanCe?
There exist only sparse data in either humans or mice 
describing the functions of innate CD8(+) T lymphocytes. An 
initial set of results consisted in a demonstration in mice of a 
protective role of IM/VM CD8(+) T lymphocytes against viral 
(30, 54) and bacterial (11) infections. Our studies have been 
focused on the numeric/functional status of innate CD8(+) 
T  lymphocytes during the multistep development of human 
tumors.
innate Cd8(+) t Lymphocytes in Chronic 
Myeloid Leukemia (CML)
Similarly to iNKT  cells (55–58), innate CD8(+) T  cells fulfill 
functions providing them with anticancer potential. Hence, a 
deficiency of these cells in CML (Box  1) on diagnosis is likely 
to constitute, as with iNKT cells (Box 2), an immune subversion 
signature. If this is indeed the case, parallel study of iNKT cells 
and innate CD8(+) T  cells in CML both at diagnosis and fol-
lowing molecular remission by tyrosine kinase inhibitor (TKI) 
therapy could perhaps answer questions concerning a dynamic 
process of generation of innate CD8(+) T cells in humans that 
would depend on iNKT cells.
There exists a major defect in the innate CD8(+) T  cells of 
chronic phase of CML (CML-CP) patients compared to those of 
healthy subjects or patients in complete remission following TKI 
treatment (41). This numerical defect is associated with a loss of 
IFN-γ expression after innate-like stimulation by IL-12 + IL-18 
cytokines and with a loss of degranulation after stimulation via 
CD16. On the contrary, IFN-γ expression after TCR stimulation 
(instead of IL-12 + IL-18 stimulation) by the same innate CD8(+) 
T cells during CP is conserved, thereby showing that the func-
tional defect affecting our population of interest is innate rather 
than adaptive. Finally, there exists a partial reconstitution in 
CML remission patients of the frequency and functions of innate 
CD8(+) T lymphocytes in terms of IFN-γ expression in response 
to IL-12 + IL-18 and as regards the displaying of cytotoxic func-
tions after CD16 stimulation.
In CML patients, the numerical and functional status of 
innate CD8(+) T  cells seems closely linked to that of the 
iNKT cells. In analysis of a cohort of CP patients and those in 
complete remission, we have observed a correlation between 
Eomes expression by innate CD8(+) T cells and PLZF expres-
sion by iNKT cells (41). This finding underscores the possible 
pathophysiological significance of IL-4 expression by iNKT cells 
in CML patients; while deficient during the CP, IL-4 expression 
is restored in remission (63) and could determine the status of 
innate CD8(+) T cells during the disease or its treatment.
More generally, a scenario can now be outlined as a possible 
explanation, during CML, for immune subversion of innate 
CD8(+) T  cells by leukemic cells. Immune subversion could 
result from dysfunction of the antigen-presenting cells (APCs), 
particularly leukemia myeloid dendritic cells (DCs) and their 
environment; they might be considered as responsible for the loss 
of function of the innate immune cells, including NK and innate 
CD8(+) T  cells. As regards iNKT  cells, their loss of function 
could be due to a loss of CD1d expression by the leukemic APCs 
expressing the BCR–ABL oncogene [Figure 5; (65)]. The loss of 
CD1d expression could reprogram iNKT cells by favoring the loss 
of PLZF expression and, consequently, of IL-4, thereby decreasing 
their capacity to orient a differentiation of CD8(+) T cells into 
innate CD8(+) T cells (Figure 5).
Another, non-exclusive hypothesis is that of a loss of IL-15 
expression by leukemic cells or of the leukemic milieu, as has 
been shown in colon cancer (66). A different study leads to the 
suggestion that during CML, TKI might favor the capacity of the 
DCs to trans-present IL-15 to T cells/NK cells (67). The scope 
of these works should be broadened, leading to a search for a 
defect in the expression and trans-presentation of IL-15 during 
CML-CP. Another relevant element is the loss in sensitivity to 
IL-15 or signalization of the latter by the innate CD8(+) T cells. 
Our preliminary results suggest a loss in response to IL-15 by total 
and innate CD8(+) T lymphocytes (Figure S4 in Supplementary 
Material). The possible implication of this loss of sensitivity to 
IL-15 in the dysregulation of the innate CD8(+) T lymphocytes 
during CML-CP remains to be investigated.
To conclude, CML can be considered as a model in study 
of the loss of innate effectors (NK cells) and innate T effectors 
[iNKT cells and innate CD8(+) T cells] and their relevance in the 
leukemic process. The escape of leukemic cells from the immune 
FigUre 5 | Continued
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FigUre 6 | innate Cd8(+) t cells are present in tumor-draining lymph nodes (tdLns) from breast cancer patients. (a) Frequencies of innate CD8(+) 
T cells among total CD8(+) T cells in axillary TDLNs were analyzed ex vivo by flow cytometry. The full cohort of five luminal breast cancer patients and one triple 
negative patient with chemotherapy is shown. Quadrant frequencies are displayed in upper right corners. (B) Clinical patient characteristics. CCI: invasive ductal 
carcinoma. CLI: invasive lobular carcinoma.
FigUre 5 | Continued 
representative view of the inKt/innate Cd8(+) t-cell axis hypothesis in chronic myeloid leukemia (CML). We propose the following scenario in CML:  
(a) steady state/healthy situation. Normal hematopoietic stem cells (HSC) generate normal immune cells. Antigens are presented via the CD1d molecule by dendritic 
cells (DCs) to iNKT cells. We propose that activated iNKT cells produce IL-4 but the possibility of a T-cell receptor (TCR)-independent mechanism for IL-4 secretion 
cannot be ruled out. IL-4 is thought to take part with IL-15 in the development/homeostasis of innate CD8(+) T cells. iNKT and innate CD8(+) T cells produce IFN-γ 
and perforin in response to the innate-like IL-12 + IL-18 stimulation. (B) Chronic phase of CML. Leukemic stem cells (LSC) produce modified immune cells bearing 
BCR–ABL translocation, including DCs. Impaired CD1d antigen presentation by DCs results from activation of the Rho/Rock pathway via the DH-PH domain of the 
ABL part of BCR–ABL. iNKT cell development/stimulation is thereby impaired, especially in terms of promyelocytic leukemia zinc-finger factor (PLZF) expression and 
IL-4 production. Consequently, we surmise that the innate CD8(+) T subset is defective in number and function. (C) Restoration of the iNKT/innate CD8(+) T-cell axis 
by therapies. IFN-α therapy is thought to help restoring DCs and innate CD8(+) T cells as well as other unidentified cells. Tyrosine kinase inhibitor (TKI) therapies 
targeting the ABL tyrosine kinase domain clear/control the generation of LSC and abnormal immune cells, including DCs. Fasudil therapy, combined with TKI, 
restores the CD1d presentation by DCs to iNKT cells and is one possible mechanism to restore the iNKT/innate CD8(+) T-cell axis.
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system could depend on loss of the coordinated functions of the 
effectors of classical innate immunity and innate T-cell immunity.
innate Cd8(+) t Lymphocytes and 
solid tumors
Since we cannot rule out the possibility that the anticancer 
role attributed to innate CD8(+) T  lymphocytes is specific to 
leukemia, we have sought to extend the scope of our hypothesis 
on the antitumor role of the innate CD8(+) T  lymphocytes by 
assessing the presence of these cells in solid tumors or metasta-
sized tissues. The characteristics of tumor micro-environments 
differ according to cancers, and it is for that reason that we have 
assessed the presence of innate CD8(+) T  lymphocytes in two 
types of solid tumors: breast cancer and ovarian cancer.
FigUre 7 | Continued
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Study of lymph nodes (LN) invaded by tumor cells in breast 
cancer has highlighted the significantly frequent presence of 
innate CD8(+) T  lymphocytes (Figure  6). The results of this 
preliminary study seem to justify organization of a large-
scale study on breast cancer patients aimed at determining a 
possible link between, on the one hand, the numerical and 
functional status of the innate CD8(+) T  cells present in the 
invaded LN draining the tumor and, on the other hand, disease 
prognosis.
Study of intra-tumoral lymphocytes in ovarian cancer has 
shown the significantly frequent presence of innate CD8(+) 
T lymphocytes, which are also present in the peritoneal carcinosis 
of ovarian cancers and in ascite fluids (Figure 7). Interestingly, 
there was a significant higher frequency of innate CD8(+) T lym-
phocytes in primitive tumors than in carcinosis (a proximity 
metastasis), indicating that these cells not only penetrate tumors 
in ovarian cancer but also might undergo immune subversion 
in the peritoneal environment. Moreover, like in CML, our data 
have shown a positive correlation between Eomes expression in 
innate CD8(+) T lymphocytes and PLZF expression in iNKT cells 
both in peripheral blood mononuclear cells (PBMCs) and tumor 
material (but not in carcinosis and ascite) from ovarian cancer 
patients (Figure 7C).
Taken as a whole, these different results show that innate 
CD8(+) T lymphocytes are present in tumors and probably inte-
grated in the dynamics of anticancer responses. However, at this 
FigUre 7 | innate Cd8(+) t cells are present in tumors and tumor fluids from ovarian cancer patients. Cells from tumors, carcinoma, peritoneal ascites, 
and peripheral blood mononuclear cells (PBMCs) from ovarian cancer patients and PBMCs from healthy individuals [healthy donors (HDs)] were analyzed ex vivo by 
flow cytometry. (a) Two representative samples reflecting the presence of innate CD8(+) T cells in tumor, carcinoma, peritoneal ascites, and PBMCs from ovarian 
cancer patients and PBMCs from two HDs. ND, not determined. (B) Cohort study of innate CD8(+) T-cell frequency [expressed as percentage ± SD of T cells 
among total CD8(+) T cells] in tumors (n = 7), carcinoma (n = 7), peritoneal fluids (n = 12), and PBMCs from ovarian cancer patients (n = 10) and PBMCs from HDs 
(n = 8). (C) Eomes and promyelocytic leukemia zinc-finger factor (PLZF) expression were analyzed in innate CD8(+) T cells [CD3(+) CD8(+) KIR/NKG2A(+) Eomes(+) 
cells] and iNKT cells [CD3(+) 6B11(+) cells], respectively. Eomes MFI values are expressed relative to that of CD45(+) CD3(−) KIR/NKG2A(−) cells. The MFI of 
PLZF-expressing iNKT cells correlate positively with Eomes MFI in innate CD8(+) T both in tumor and PBMCs but not in carcinosis (r = −0.04673, p = 0.8853) and 
ascites (r = 0.5424, p = 0.2084) from ovarian cancer patients (correlation Spearman test). (d) Clinical patient characteristics. NA, not available.
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time, it is not possible to determine their intra-tumoral functional 
status and, more specifically, their prognostic usefulness.
innate Cd8(+) t Lymphocytes and 
immune exhaustion in Cancer patients
Numerous studies have dealt with the role of Eomes in the 
exhaustion of CD8(+) T  lymphocytes during chronic infec-
tions or cancers (68–72). Our results in healthy donors (HDs) 
attesting a significant proliferative response to IL-15 (Figure S4 
in Supplementary Material) do not lend support to an exhaus-
tion phenotype of innate CD8(+) T cells in normal conditions. 
During cancer progression, on the other hand, the elevated 
frequency of innate CD8(+) T lymphocytes in contact with the 
tumor present in severely ill patients raises the question of their 
possible exhausted immune-exhaustion status. Furthermore, 
during CML, we have observed a functional defect in the innate 
CD8(+) T-cell population, a finding suggesting not only that CML 
innate CD8(+) T cells are in the process of being exhausted but 
also that they could be a target of immune blocking checkpoints. 
Monitoring multifunctionality of immune-exhausted CD8(+) 
T cells co-expressing Eomes and KIR/NKG2A in patients with 
solid tumors and CML will help to determine whether the evasion/
subversion mechanisms used by tumor cells also apply to innate 
CD8(+) T cells in humans. At this stage, it would be interesting to 
determine whether the innate CD8(+) T cells express CXCR3 and 
CXCR5, two chemokine receptors that were recently described as 
being associated with CD8(+) T lymphocytes during cancers or 
chronic viral infection and of which the proliferation is restored 
following anti-programmed cell death 1 treatment (73).
ConCLUsion
Taken together, having availed ourselves of different types of 
empirical data, we propose that in humans, innate CD8(+) 
T  lymphocytes constitute a new cellular component that could 
have a role in antitumor immunity. Our results during CML and 
ovarian cancer are in favor of the existence of an axis composed 
of innate T cells with an antitumoral potential, which consist of 
iNKT  cells and innate CD8(+) T  lymphocytes. Differentiation 
of these unconventional CD8(+) T  cells in humans is associ-
ated with Eomes expression and could depend on IL-4 and 
PLZF(+) iNKT cells. Our results suggest that during CML, these 
innate CD8(+) T  lymphocytes could be controlled by immune 
checkpoints. While the results of our studies on solid cancers 
corroborate our hypothesis concerning the role of innate CD8(+) 
T lymphocytes in antitumor immunity, as of now we are unable 
to determine whether this role is protective, permissive, and/or 
detrimental in these other types of cancer.
MetHods
pBMCs from Hd
Healthy donors were volunteers from the Pôle Biologie Santé 
(Poitiers, France). PBMCs were isolated from blood samples 
by density gradient centrifugation (Histopaque®-1077, Sigma-
Aldrich), resuspended in 90% fetal calf serum with 10% DMSO, 
and placed in a controlled rate freezer for cryopreservation at 
−80°C until use. For this series of data, age range was between 21 
and 65 with a sex ratio of 0.6.
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Clinical Breast and ovarian Cancer 
samples
Invaded tumor-draining lymph nodes were collected from six 
untreated luminal breast cancer patients undergoing standard 
surgery at Institute Curie Hospital (Paris, France), in accord-
ance with institutional ethical guidelines. Precisely, all patients 
gave informed consent in a written form in accordance with the 
Declaration of Helsinki for participation in this study, which 
was approved by the scientific committee of the Institute Curie 
Hospital.
Cells from tumors, carcinomatosis, peritoneal ascites, and 
PBMCs were collected from eight untreated patients with ovar-
ian carcinoma undergoing standard surgery at CHU of Rennes. 
Human samples were obtained from the processing of biological 
samples through the Centre de Resources Biologiques Santé of 
Rennes (BB-0033-00056). The research protocol was conducted 
under French legal guidelines and fulfilled the requirements of 
the local institutional ethics committee.
Tissue samples were cut into small fragments, digested with 
0.1  mg/ml Liberase TL (Roche) in the presence of 0.1  mg/ml 
DNase (Roche) for 15–30 min before the addition of 20% FCS. 
Cells were filtered on a 40-μm cell strainer (BD), washed, and 
cryopreserved for further study. Ascite cells were obtained after 
centrifugation (400 g, 10 min).
experimental studies in animals
The 8-to-12-week-old female C57BL/6JRj Eomes-GFP transgenic 
mice (74) and BALB/c wild-type mice (Janvier) were used and 
bred in our animal facility (PREBIOS, Platform of Research and 
Experimentation in Health Biology of the University of Poitiers) 
under specific pathogen-free conditions. Spleen and thymus were 
collected immediately after cervical dislocation. Splenocytes and 
thymocytes were isolated and analyzed ex vivo by flow cytometry. 
In some experiments, splenocytes were cultured for 16 h in the 
presence of 20  ng/ml of each cytokine (IL-12: R&D Systems; 
IL-18: MBL International) prior to analysis by flow cytometry. 
All procedures were performed in accordance with the recom-
mendations of the European Accreditation of Laboratory Animal 
Care and French institutional committee of Poitou-Charentes 
(COMETHEA, C2EA-84, no. 2016072216352833).
Cell Culture and Functional assays
Peripheral blood mononuclear cells (1  ×  106  cells/ml) were 
cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated FCS and antibiotics. For IL-12  +  IL-18 or IL-15 
stimulation, PBMCs from HD were seeded at 1.106 cells/ml 
into 24-well plates and incubated for 48 h with 20 ng/ml of each 
cytokine (IL-12: R&D Systems; IL-18: MBL International; IL-15: 
Miltenyi). Golgistop (BD Biosciences) was added for the last 5 h 
of culture for IL-12 + IL-18 stimulation.
Flow Cytometry
In humans, phenotypic analysis of cells from HD or breast/
ovarian cancer patients was performed by flow cytometry 
either ex vivo or after culture. Expression of different markers 
was assessed by staining with appropriate combinations of the 
following antibodies (mAbs): anti-TCR-αβ BV421 (clone: IP26, 
BioLegend), anti-CD8 PE-Cy7 (clone: RPA-T8, Biolegend), anti-
IFN-γ FITC (clone: B27, BioLegend), anti-TCR-Vα7.2 BV421 
(clone: 3C10, BioLegend), anti-CD161 PerCP-Cy5.5 (clone: 
HP-3G10, Biolegend), and anti-Eomes eFluor® 660 (clone: 
WD1928, eBiosciences). KIR/NKG2A referred to staining with 
the mix of the three following antibodies from Miltenyi Biotech: 
anti-KIR2D PE (clone: NKVFS1), anti-KIR3DL1/KIR3DL2 
(CD158e/k) PE (clone: 5.133), and anti-NKG2A (CD159a) PE 
(clone: REA110). For nuclear Eomes staining and intracytoplas-
mic IFN-γ staining, cells were permeabilized with an anti-human 
FoxP3 staining kit (eBioscience) and a Cytofix/Cytoperm kit (BD 
Biosciences), respectively.
In mice, splenocytes and thymocytes were stained with appro-
priate combinations of the following antibodies: anti-TCR-β 
PerCP-Cy5.5 (clone: H57-597, BD Biosciences), anti-CD8 BV510 
(clone: 53-6.7, BD Biosciences), anti-CD44 PE-Cy7 (clone: IM7, 
BD Biosciences), anti-CD49d Vioblue (clone: R1-2, Miltenyi 
Biotec), anti-CD122 APC (clone: TM-B1, Biolegend), anti-CD4 
PE (clone: RM4-5, BD Biosciences), anti-CD24 PE (clone: M1/69, 
BD Biosciences), and anti-Eomes AF488 (clone: Dan11mag, 
eBioscience). For nuclear Eomes staining and intracytoplasmic 
IFN-γ staining, cells were permeabilized with an anti-human 
FoxP3 staining kit (eBioscience).
Dead cells were excluded using the Live/Dead® Fixable NearIR 
Dead Cell Stain kit (Life Technologies). Cells were analyzed on 
a Fortessa flow cytometer (BD Biosciences) or a FACSVerse™ 
cytometer with FACSuite™ software (BD Biosciences) using 
FlowJo v10 (TreeStar, Inc.).
statistical analysis
Statistical analyses were performed using GraphPad Prism 
version 7.0 (GraphPad Software). The statistical significance 
of differences and of mean values was analyzed by the two-
tailed Wilcoxon test in Figure 3, paired t-test in Figure 4, and 
Mann–Whitney non-parametric test in Figure  7. Results were 
considered to be statistically significant when p < 0.05.
etHiCs stateMent
All patients gave informed consent in a written form in accord-
ance with the recommendations of “the Declaration of Helsinki” 
for participation in the study, which was approved by the 
scientific committees of the Clinic Investigator Center Inserm 
CIC-1402 (Poitiers, France), the Biological Resource Center of 
CHU of Poitiers (NF S96-900 certification since February 2014), 
the Biological Resource Center of CHU of Rennes (NF S96-900, 
certification since May 2009), and the Institute Curie Hospital 
(Paris, France).
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